Takeda reported that its AI-designed oral psoriasis candidate zasocitinib achieved complete skin clearance in more than 35% of patients at 16 weeks in a Phase 3 study, outperforming Bristol Myers Squibb’s Sotyktu comparator. Takeda said the response rate was more than 2.5 times that of patients receiving Sotyktu in the study. The company reported efficacy separation as early as week 8 and also beat Sotyktu on key secondary outcomes including PASI 90. Takeda said the data support regulatory filing plans in coming months. Takeda previously acquired zasocitinib from Nimbus Therapeutics for $4 billion and has been positioning the TYK2-targeting, IL-23-inhibiting approach to deliver rapid and durable clearance in a convenient once-daily pill.